The decision patients actually face

A diagnosis of cartilage damage in the mid-40s or early 50s puts patients in an uncomfortable middle ground: the knee hurts enough to affect daily life, but a knee replacement feels premature. Understanding why that instinct is clinically sound — and what the genuine options are — is where a good decision starts.

Articular cartilage has virtually no capacity for self-repair. When a focal, full-thickness defect develops, the surrounding tissue cannot fill the gap; left untreated, the exposed bone surface wears progressively, and what begins as a localised problem can develop into diffuse degenerative arthritis over time.

Total knee replacement (TKR) offers a compelling long-term record — published series report ten-year success rates exceeding 90%, with prostheses remaining functional well past 15 to 20 years. The problem for younger patients is what happens next. Implants placed in people under 55 carry a substantially higher risk of requiring revision within 20 years, and revision surgery is more complex, with less predictable outcomes than the original procedure.

This is the opening for cartilage repair: not as a way to compete with TKR on longevity, but as a joint-preservation pathway suited to a different point on the disease timeline. The question is not simply 'repair or replace?' but rather whether a given patient — based on age, defect size, alignment, and overall joint health — is at the right stage for repair to offer meaningful benefit.

The patient profile that makes cartilage repair viable

Cartilage repair is not a universal option — it works within a fairly precise set of clinical boundaries. Running through those boundaries is a practical first step before any specialist appointment.

Age and activity level. Most cartilage repair procedures are designed for patients under 50–55 who lead an active life. Biological age matters here: the threshold exists because the procedures must outlast many years of daily joint loading, and the evidence base is built largely on this younger cohort.

Defect size and location. The damage needs to be focal — contained to one defined area of the joint surface rather than spread across multiple compartments. Diffuse or multi-compartmental osteoarthritis places a patient outside the repair pathway, not because repair is refused, but because rebuilding a small patch of cartilage in a globally worn joint does not change the joint's overall trajectory.

Joint stability and alignment. A structurally sound knee is a prerequisite. Where malalignment is the underlying cause of localised cartilage loading — a 'bow-legged' or 'knock-kneed' mechanical axis — osteotomy (reshaping the tibia or femur to redistribute load) may correct the problem and, in some cases, make a patient who initially appeared borderline suitable for a repair procedure. This is worth discussing with a specialist rather than assuming malalignment rules out repair entirely.

Body weight. A BMI below 30 is a standard eligibility threshold. Above that level, the mechanical forces on a repaired cartilage surface significantly worsen outcomes, and most programmes will not proceed until weight has been reduced.

Disqualifying factors. Inflammatory arthritis — including rheumatoid arthritis — is an exclusion, as the underlying immune process would continue to damage any repaired tissue. Prior failed marrow-stimulation procedures (such as microfracture) can compromise the subchondral bone in ways that limit later options. Significant medical comorbidities affecting healing or anaesthetic risk are assessed individually.

Not meeting one or more of these criteria is not a dead end — it points toward a different, equally valid pathway, whether that is an optimised non-surgical programme, a joint-preservation approach suited to a different disease stage, or, where appropriate, early planning for replacement.

Conservative treatment must come first

Reaching a cartilage repair assessment without first working through non-surgical management is unusual — most surgeons will not consider operative options until a structured conservative programme has been completed and documented.

Physiotherapy is the cornerstone. Targeted strengthening of the muscles around the knee — particularly the quadriceps and hip stabilisers — reduces the compressive load transmitted through the joint with every step. Movement pattern correction, where a physiotherapist addresses gait or biomechanical habits that concentrate load unevenly, adds further protection. This is not a passive holding strategy; it directly changes the mechanical environment the cartilage must survive.

Weight loss has a measurable effect on joint loading: studies suggest each kilogram of body weight equates to roughly three to four kilograms of force across the knee during walking. Clinicians expect documented effort here before surgical options are considered.

Anti-inflammatory medication and activity modification manage pain during this phase without addressing the structural problem — they create space for the programme to work.

Unloader bracing can shift force away from the affected compartment, which is particularly relevant where mild malalignment contributes to focal overloading.

Biologic injections — hyaluronic acid, platelet-rich plasma (PRP), and similar options — may be offered alongside this programme to reduce symptoms. In suitable repair candidates, they function as adjuncts to the conservative phase rather than as a substitute for a restorative procedure; patients who go on to cartilage repair will typically have tried them without achieving lasting relief.

The techniques available and which defects they suit

The restorative options span a spectrum from outpatient injection to two-stage cell-based surgery, each matched to a different defect size and clinical scenario. Six main pathways are in current use.

ChondroFiller injection (injectable collagen scaffold). An acellular scaffold delivered via ultrasound-guided outpatient injection — no theatre, no general anaesthetic. The collagen matrix recruits the patient's own progenitor cells to stimulate repair through matrix-induced chondrogenesis. Suited to focal defects up to approximately 3 cm², with some evidence supporting use up to 6 cm². Single-stage; minimal procedural downtime.

OATS / Mosaicplasty (osteochondral autograft transfer). A single-stage procedure that moves a cylindrical plug of healthy bone and cartilage from a low-load area of the same knee into the defect. Best suited to defects of 1–2 cm²; the mosaic variant covers up to approximately 4 cm² using multiple plugs. Donor-site morbidity — discomfort or low-grade symptoms at the harvest site — is a recognised trade-off.

AMIC (matrix-augmented microfracture). A single-stage bridge between basic marrow stimulation and cell-based repair. Microfracture is performed first to release bone marrow cells, then a scaffold matrix is added to improve cell retention and tissue organisation — providing more structural support than microfracture alone without the two-stage commitment of ACI or MACI.

MACI / ACI (cell-based implantation). Two-stage procedures for defects of roughly 2–10 cm². A first-stage biopsy harvests the patient's own cartilage cells; these are cultured in a laboratory and, in MACI, seeded onto a collagen membrane before implantation. The SUMMIT randomised controlled trial demonstrated that MACI outperformed microfracture on pain and function at two years, with benefits sustained to five years. Resource-intensive, but the strongest comparative evidence base among surgical options.

OCA (osteochondral allograft). A single-stage procedure using donor tissue for larger or posttraumatic defects where the patient's own tissue is insufficient. Long-term follow-up data exist, though the evidence base is thinner than for cell-based techniques.

Microfracture. Historically the first-line option for small defects under 2 cm², this marrow-stimulation technique is now declining in clinical use. Published data report less than 60% survivorship at three years, with functional scores often falling between 18 and 36 months after surgery. Of particular concern, microfracture can damage the subchondral bone plate in ways that limit future repair options — a significant drawback for younger patients who are likely to need further intervention.

Defect size is only one factor; location, prior procedures, and individual biology all influence which pathway a specialist will recommend.

What outcomes to realistically expect

For most patients, the honest answer to 'how well will this work?' falls between meaningful functional improvement and genuine uncertainty about long-term durability.

The SUMMIT trial evidence — discussed alongside the techniques in the previous section — confirms that MACI delivers superior pain relief and function at two and five years compared with microfracture. In practical terms, that means reduced pain during ordinary activities: walking, climbing stairs, low-impact exercise. The realistic goal of any cartilage repair procedure is a restored joint surface that holds up for daily life and light recreational sport. Return to high-impact or contact sport is unpredictable and should not be the primary driver of the decision; specialists typically frame outcomes around years of comfortable function rather than athletic performance benchmarks.

For cell-based techniques more broadly, longer-range follow-up — including a minimum ten-year study by Minas and colleagues published in 2014 — supports meaningful durability, though that evidence reflects earlier-generation ACI rather than current practice.

Against this sits the benchmark introduced at the start of this article: total knee replacement's long-term track record is difficult to match for longevity alone. The case for cartilage repair rests not on competing with that record but on deferring it — preserving native tissue in a patient too young to commit to a prosthesis carrying substantial revision risk before the age of 55.

The evidence gap is worth naming plainly. Head-to-head data comparing cartilage repair with watchful waiting or early replacement in the under-50 population remain limited. What this means practically is that durability beyond a decade is genuinely variable across individuals — not merely understudied — and expectations should be set accordingly in consultation with a specialist.

Finding a specialist who covers your options

Volume and sub-specialty focus matter when choosing a surgeon. Not every knee specialist performs MACI, ACI, or osteotomy regularly, and experience with a specific technique shapes both patient selection and the realistic conversation about outcomes. A surgeon whose practice spans both cartilage repair and joint replacement is generally better placed to give unbiased guidance than one whose workload is weighted heavily towards arthroplasty.

Three questions are worth bringing to a first consultation: Which technique would you recommend for my defect size and location, and why? How often do you perform this procedure? And — honestly — what does a good outcome look like for a patient at my stage?

Specialists across the UK offering cartilage repair and joint-preservation surgery are listed on Search MSK; filtering by region and specialty is a practical starting point for finding someone with the right remit.

For the right patient — younger, with a focal defect in an otherwise stable knee — cartilage repair is not a gamble against the evidence. It is what the evidence, carefully read, actually supports.